Cutler Group LP Genmab A/S Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 18, 2022	SELL	$35.87 - $47.12 $3,586 - $4,712	-100 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$41.55 - $48.72 $4,155 - $4,872	100 New	100 $4,000
Q2 2021 Jul 19, 2021	SELL	$32.88 - $44.57 $6,576 - $8,914	-200 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$30.92 - $44.4 $3,092 - $4,440	100 Added 100.0%	200 $6,000
Q3 2020 Oct 27, 2020	BUY	$33.07 - $38.68 $3,307 - $3,868	100 New	100 $3,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.